AACRpublished
Abstract 1665: Preclinical characterization of IPN60300, a first-in-class ITGA2 antibody-drug conjugate for cancer therapy
AACR published a preclinical characterization abstract for IPN60300, an ITGA2-targeting antibody-drug conjugate for cancer therapy.
2026-04-03 Foreseen Biotechnology Public article URL ready for sharing
AACR Journals published Abstract 1665 in Cancer Research, reporting preclinical characterization of IPN60300 as a first-in-class ITGA2 antibody-drug conjugate for cancer therapy.
The record supports the IPN60300 / FS001 news context by documenting preclinical evidence around the ITGA2-targeting ADC program.
Source: Cancer Research / AACR Journals. DOI: https://doi.org/10.1158/1538-7445.AM2026-1665.
Collaboration & media inquiries
For additional information about the platform, pipeline or partnership opportunities, submit an inquiry through the contact page.
Contact Foreseen